Compare GASS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GASS | VNDA |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.4M | 301.1M |
| IPO Year | 2005 | 2005 |
| Metric | GASS | VNDA |
|---|---|---|
| Price | $9.22 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 107.2K | ★ 756.2K |
| Earning Date | 11-24-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $6.22 | $4.27 |
| 52 Week High | $10.55 | $9.91 |
| Indicator | GASS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 31.06 |
| Support Level | $9.10 | $4.45 |
| Resistance Level | $9.83 | $5.37 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 33.77 | 14.80 |
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.